1627

TECH CENTER 1800/80

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, 20231 on July 2, 2002.

Stephen A. Slusher, Reg. No. 43,924

July 2, 2002 (Date Signed)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Shubh D. Sharma, et al.

Serial No.: 10/049,718

J.. 10/043,7 10

Filed:

February 13, 2002

For: Melanocortin Metallopeptide Constructs,: Combinatorial Libraries and Applications :

Examiner: UNKNOWN

Group Art Unit: 1627

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION (37 CFR § 1.97(b))

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last. 37 CFR § 1.97(b).

Dated: July 2, 2002

By:

Stephen A. Slusher Reg. No. 43,924

Direct line: (505) 998-6130

Attorneys for Applicant(s)
PEACOCK, MYERS& ADAMS, P.C.
P.O. BOX 26927
Albuquerque, New Mexico 87125-6927

Telephone: (505) 998-1500

Facsimile: (505) 243-2542

[F:\MIKE\PATENT\Palatin-Rhomed\MELANOCORTIN METALLO\IDS Trans.doc]

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Kn wn						
Application Number 10/049,718						
Filing Date	February 13, 2002					
First Named Inventor	Shubh D. Sharma					
Group Art Unit	1627					
Examiner Name						
Attorney Docket Number	70025-02-US02					

				U.S. PATENT DOC	JMENTS	
Examiner Initials	Cite No.1	Number (ii k	ment   Code² nown)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		5,891,418		Sharma	04/06/1999	
		6,027,711	L	Sharma	02/22/2000	<u> </u>
		5,690,905	$\mathbb{L}^{-}$	Zamora	11/25/1997	
		5,200,504		Ghadiri /	04/06/199:	
		5,277,893		Rhodes	01/11/1994	
						1609/
						1800/290
						90
			Ш			-0
			L.,			
			$\square$			
$\longrightarrow$						
			$\sqcup$			
			$\sqcup$			
			l I			

			FORE	IGN PATENT DOCUMEN	TS		
Examiner Cite	F	oreign Patent Do	cument		,	Pages, Columns, Lines,	$\top$
No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	1
							$\top$
	<del>                                     </del>	<del></del>					
	<del>                                     </del>						$\perp$
	<del>                                     </del>						L
	<del> </del>	<del></del>			ļ		1
	<del>                                     </del>			<del></del>			丄
	Cite No.1	Cite	Cite	Cite Foreign Patent Document  Kind Code <sup>5</sup>	Cite Foreign Patent Document Name of Patentee or	Cite Foreign Patent Document  Name of Patentee or Applicant of Cited Document  No.1 Office3 Number Applicant of Cited Document	Cite No.1 Office3 Number4 (if known) Name of Patentee or Applicant of Cited Document Applicant of Cited Document Name of Patentee or Applicant Option Name of Patentee Option Name

Examiner Date	
Signature Consi	ered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

	us sign (+) inside this work Reduction Act o				PTO/SB/08B (08-00) ed for use through 10/31/2002. OMB 0651-0031 ark Office: U.S. DEPARTMENT OF COMMERCE n unless it contains a valid OMB control number.	4
<i>[</i>	te for form 1449B/PT		PADEMARY	R/		
INIE	ADMATIO!			Application Number	10/049.718	
			DISCLOSURE	Filing Date	February 13. 2002	
STATEMENT BY APPLICANT				First Named Inventor	SHARMA. Shubh D.	
i				Group Art Unit	1627	
	(use as many s	sheel	ts as necessary)	Examiner Name	;	
Sheet	2	of	2	Attorney Docket Number	70025-02-US02	

	T	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cile No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		ROYO, Miriam, et al., "S-Phenylacetamidomethyl (Phacm): an orthogonal cysteine protecting group for Boc and Fmoc solid-phase peptide synthesis	
		strategies, J.Chem. Soc., ed: May 7, 1995; pp.1095-1102.	
		GALLOP, Mark A., et al., "JOURNAL OF MEDICINAL CHEMISTRY," Vol. 37, No. 6; Applications of	
		Combinatorial Technologies to Drug Discovery; April 29, 1994; pp. 1233-1251.	
			1
			1
			+
	-		+
	_		+
	$\dashv$		+
<del></del>			丄

Examiner	· ·	Date	
Signature		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademerk Office, Washington. DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.